Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset of patients remains refractory to ADC treatment.  WuXi AppTec contributed to a research article which demonstrated that excessive cancer-associated fibroblasts (CAFs) can form a fibrotic barrier within a tumor microenvironment, impeding the tissue uptake of …Read More >

BRCA1 and BRCA2 proteins are key components of the homologous recombination repair pathway for repairing double-stranded DNA breaks.  Mutations in BRCA genes can significantly increase the risk of certain cancers such as breast, ovarian, pancreatic, and prostate cancer. To mimic the effects of BRCA2 deficiency in humans, WuXi Biology has constructed a BRCA2 deficient mouse …Read More >

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you our preclinical pharmacological evaluation platform for T cell engagers. https://onco.wuxiapptec.com Introduction T-cell engagers (TCEs) are …Read More >

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug, several new strategies have recently become available for targeting the mutant protein. One of the most promising of these involves the use of low molecular weight compounds that promote refolding and reactivation of mutant p53 …Read More >

Frequently observed in NSCLC patients, the 4 amino acid YVMA insertion is the most common type of HER2 exon 20 insertion mutation. A secondary mutation, C805S, often develops as a mechanism of resistance to HER2 tyrosine kinase inhibitors (TKIs) such as poziotinib, where the C805 residue is crucial for drug binding.  The presence of a …Read More >

Homozygous deletion of methylthioadenosine phosphorylase (MTAP) in cancers such as glioblastoma represents a potentially targetable vulnerability. MTAP deletions occur in approximately 10 – 15% of all human cancers. When the MTAP gene is deleted, methylthioadenosine (MTA) accumulates and selectively inhibits PRMT5. This creates a synthetic lethal dependence on PRMT5 in MTAP-deleted tumors. As a potential …Read More >

Since prostate cancer heavily depends on androgen hormones for growth, targeting the androgen receptor (AR) signaling pathway is a key therapeutic strategy for treating advanced metastatic prostate cancer. While AR antagonists like enzalutamide can significantly improve survival in prostate cancer patients, resistance often develops over time, largely driven by treatment-induced mutations within the ligand-binding domain …Read More >

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share our experience with mRNA drug development and their anti-tumor efficacy. OncoWuXi Introduction to Nucleic Acid Drugs RNA-based therapies …Read More >

Research on cancer immunotherapy has firmly established immune cells as key players in effective cancer treatment. Peptide vaccines directly targeting immune cells have demonstrated immense potential due to their specificity and applicability, but developing peptide vaccines to generate tumor-reactive T cells remains challenging. WuXi AppTec contributed to a review article discussing various elements of effective …Read More >